Traded Apr 30 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Apr 2, 2026 · Filed Apr 3, 2026
United Therapeutics's & GENERAL COUNSEL sold $435K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$435,254
Shares × reported transaction price
36 days after results of Feb 25, 2026, 34 days before results of May 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Traded Apr 30 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Martine A Rothblatt (Chairperson & CEO) sold ~$205K of United Therapeutics
Scheduled in advanceMartine A Rothblatt (Chairperson & CEO) sold ~$681K of United Therapeutics
Scheduled in advance